Status:
UNKNOWN
Algorithms to Diagnose Pulmonary Arterial Hypertension
Lead Sponsor:
RenJi Hospital
Collaborating Sponsors:
Shanghai Zhongshan Hospital
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Pulmonary Arterial Hypertension
Eligibility:
All Genders
18-75 years
Brief Summary
The investigators intend to evalute the value of radiomics signature of pulmonary vessels from chest computed tomography (CT) for dianosis and prognosis of pulmonary arterial hypertension.
Detailed Description
Pulmonary arterial hypertension (PAH) is a heterogeneous disorder composed of varying pathobiology that may involve multiple clinical conditions. Computed tomography (CT) is a minimally invasive imagi...
Eligibility Criteria
Inclusion
- Chest CT examination and cardiac ultrasound examination were performed within 3 months before and after right heart catheterization;
- mPAP \> 25mmHg and PVR\< 3woods (measured by right heart catheter) and pulmonary vascular resistance was collected as PAH group whereas Healthy Volunteers as non-PAH control group in developement corhort;
- sPAP \> 36mmHg (measured by echocardiography) was collected in validation corhort.
Exclusion
- Cancer; 2. The quality of chest CT and cardiac ultrasound images is poor; 3.Pulmonary vascular segmentation is affected by thoracic organ displacement or pulmonary vascular complete occlusion due to diseases ,such as spinal deformity.
Key Trial Info
Start Date :
January 17 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 1 2023
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT05417373
Start Date
January 17 2019
End Date
June 1 2023
Last Update
June 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Renji Hospital
Shanghai, China, 200127